These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 2510503

  • 21. Plasma and platelet von Willebrand factor defects in uremia.
    Gralnick HR, McKeown LP, Williams SB, Shafer BC, Pierce L.
    Am J Med; 1988 Dec; 85(6):806-10. PubMed ID: 3264111
    [Abstract] [Full Text] [Related]

  • 22. von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma.
    Holmberg L, Berntorp E, Donnér M, Nilsson IM.
    Blood; 1986 Sep; 68(3):668-72. PubMed ID: 3488775
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M, Kimura A, Chiba Y, Yoshida Y.
    Thromb Haemost; 1988 Jun 16; 59(3):485-90. PubMed ID: 3142084
    [Abstract] [Full Text] [Related]

  • 25. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 16; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 26. The RIIIS/J inbred mouse strain as a model for von Willebrand disease.
    Sweeney JD, Novak EK, Reddington M, Takeuchi KH, Swank RT.
    Blood; 1990 Dec 01; 76(11):2258-65. PubMed ID: 2124152
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Clinical significance of inhibitors in acquired von Willebrand syndrome.
    Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T.
    Blood; 1998 May 15; 91(10):3623-9. PubMed ID: 9572997
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
    Casonato A, Pontara E, Sartorello F, Bertomoro A, Durante C, Girolami A.
    J Lab Clin Med; 2001 Jan 15; 137(1):70-6. PubMed ID: 11150026
    [Abstract] [Full Text] [Related]

  • 33. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van Vliet HH.
    Acta Haematol; 2009 Jan 15; 121(2-3):85-97. PubMed ID: 19506353
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand factor platelet interaction, and the presence of all von Willebrand factor multimers in plasma.
    Casonato A, De Marco L, Mazzucato M, De Angelis V, De Roia D, Fabris F, Ruggeri ZM, Girolami A.
    Blood; 1989 Nov 01; 74(6):2028-33. PubMed ID: 2804346
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.